The company is testing Carvykti in multiple myeloma patients, with a history of relapse, who have stopped responding to existing treatment and have received one to three prior therapies.
If you are not happy with the results below please do another search
50 search results for:
The FDA approved Merck’s Keytruda for the treatment of stage IB, II or IIIA non-small cell lung cancer after resection or platinum-based chemotherapy.
The companies announced today that the EU approval is indicated for treating children as young as 6 months old with severe atopic dermatitis.
As the industry leader in delivering complementary, integrated and specialized capabilities across the commercialization continuum, Fulling will be accountable for the overall strategy, organizational leadership, financial performance, and next-level growth of this market-leading commercial enterprise.
The application to the EMA was based on results from a late-stage study that showed the drug slowed down the rate of cognitive decline in patients with early Alzheimer’s by 27%, compared with a placebo.
The treatment is not expected to neutralize the currently dominant XBB.1.5 subvariant of Omicron.
Cannabis products, excluding Jazz Pharmaceuticals Plc’s epilepsy drug Epidiolex, are illegal at the federal level in the United States, although some states allow their use.
As the healthcare journey for patients living with cancer has changed, so has the way in which pharmaceutical companies bring a drug to market. Med Ad News spoke with Anne Marie Robertson, SVP, strategy & marketing, EVERSANA about how companies need to rethink traditional commercialization models in oncology to be agile in today’s market.
Although nearly all the countries in Europe are reporting shortages, the EMA is not going to label the ongoing shortage of antibiotics in the continent a “major event”, according to a source familiar with the matter.
Following the death of a patient, Magenta Therapeutics placed a hold on Phase I/II dose-escalation trial of its acute myeloid leukemia therapy.